AI-Powered Multi-Cancer Early Screening Goes Mainstream: One Blood Test Detects 10 Early-Stage Solid Tumors
A blood-based circulating tumor DNA (ctDNA) analysis combined with deep learning has received regulatory certification, enabling annual multi-cancer screening for 10 high-incidence cancers through a single blood draw.
Screening Coverage
| Cancer Type | Sensitivity | Specificity |
|---|---|---|
| Lung cancer | 92% | 98% |
| Liver cancer | 88% | 97% |
| Gastric cancer | 85% | 96% |
| Colorectal cancer | 90% | 98% |
| Pancreatic cancer | 78% | 95% |
| Breast cancer | 87% | 97% |
| Ovarian cancer | 82% | 96% |
| Thyroid cancer | 89% | 99% |
| Kidney cancer | 84% | 97% |
| Prostate cancer | 80% | 94% |
Technology
Liquid Biopsy + AI
After a blood draw, the test analyzes methylation patterns in circulating tumor DNA (ctDNA) against a trained multi-cancer model. The AI examines ctDNA epigenetic signatures to determine the tissue of origin of any tumors, achieving 85% localization accuracy.
Early Detection Advantage
Traditional imaging typically only detects tumors larger than 5mm. Liquid biopsy can detect early-stage signals below 3mm. Early detection raises 5-year survival rates by an average of 40 percentage points across cancer types.
Adoption Status
Insurance Coverage
Zhejiang and Beijing have taken the lead in covering multi-cancer screening under basic medical insurance for residents over 45, with the ¥600 annual test reimbursed by insurance.
Checkup Centers Upgrade
Major checkup chains are adding "AI Cancer Screening" packages as a new revenue driver. One national chain reported a 25% increase in premium health checkup orders since launching the package.
Caveats
Oncologists caution that screening carries false positive risks, where positive results may lead to unnecessary follow-up procedures and patient anxiety. Sensitivity for highly aggressive cancers like pancreatic cancer remains insufficient, and this screening cannot replace existing specialized screening programs.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.